X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
3.980
+0.180 (4.74%)
At close: Dec 5, 2025, 4:00 PM EST
3.970
-0.010 (-0.25%)
After-hours: Dec 5, 2025, 6:37 PM EST
X4 Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 33.98 | 2.56 | - | - | - | 3 | Upgrade
|
| Cost of Revenue | 5.7 | 0.8 | - | - | - | - | Upgrade
|
| Gross Profit | 28.28 | 1.76 | - | - | - | 3 | Upgrade
|
| Selling, General & Admin | 46.28 | 61.52 | 35.51 | 27.02 | 24.7 | 20.94 | Upgrade
|
| Research & Development | 73.7 | 81.64 | 72.02 | 61.06 | 50.65 | 41.93 | Upgrade
|
| Operating Expenses | 119.98 | 143.16 | 107.52 | 88.08 | 75.35 | 62.87 | Upgrade
|
| Operating Income | -91.7 | -141.4 | -107.52 | -88.08 | -75.35 | -59.87 | Upgrade
|
| Interest Expense | -8.99 | -8.77 | -5.78 | -3.99 | -3.64 | -2.69 | Upgrade
|
| Interest & Investment Income | 3.86 | 5.77 | 4.58 | 0.22 | 0.01 | 0.27 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.33 | -0.33 | 0 | - | - | -4.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.57 | 2.59 | 7.63 | -2.5 | 0.06 | 4.84 | Upgrade
|
| EBT Excluding Unusual Items | -87.6 | -142.14 | -101.09 | -94.35 | -78.92 | -61.82 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -9.76 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 105 | - | 0.51 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -0.16 | Upgrade
|
| Pretax Income | -94.8 | -37.14 | -101.09 | -93.84 | -88.68 | -61.98 | Upgrade
|
| Income Tax Expense | 0.3 | 0.31 | 0.08 | 0.03 | 0.02 | 0.15 | Upgrade
|
| Net Income | -95.1 | -37.45 | -101.17 | -93.87 | -88.7 | -62.13 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 2.55 | 13.94 | - | Upgrade
|
| Net Income to Common | -95.1 | -37.45 | -101.17 | -96.41 | -102.64 | -62.13 | Upgrade
|
| Shares Outstanding (Basic) | 16 | 7 | 6 | 2 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 7 | 6 | 2 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 141.76% | 13.08% | 179.91% | 146.71% | 28.25% | 74.13% | Upgrade
|
| EPS (Basic) | -5.90 | -5.59 | -17.07 | -45.53 | -119.59 | -92.84 | Upgrade
|
| EPS (Diluted) | -5.90 | -5.59 | -17.07 | -45.53 | -119.59 | -92.84 | Upgrade
|
| Free Cash Flow | -103.13 | -131.23 | -96.57 | -77.21 | -71.52 | -60.18 | Upgrade
|
| Free Cash Flow Per Share | -6.40 | -19.58 | -16.29 | -36.46 | -83.33 | -89.92 | Upgrade
|
| Gross Margin | 83.24% | 68.83% | - | - | - | 100.00% | Upgrade
|
| Operating Margin | -269.87% | -5529.96% | - | - | - | -1995.80% | Upgrade
|
| Profit Margin | -279.86% | -1464.61% | - | - | - | -2071.03% | Upgrade
|
| Free Cash Flow Margin | -303.50% | -5132.07% | - | - | - | -2006.00% | Upgrade
|
| EBITDA | -90.37 | -140.61 | -107.1 | -87.57 | -74.85 | -59.52 | Upgrade
|
| D&A For EBITDA | 1.33 | 0.8 | 0.42 | 0.51 | 0.5 | 0.35 | Upgrade
|
| EBIT | -91.7 | -141.4 | -107.52 | -88.08 | -75.35 | -59.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.